Compare BWEN & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | CVM |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 43.3M |
| IPO Year | N/A | 1987 |
| Metric | BWEN | CVM |
|---|---|---|
| Price | $3.58 | $5.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 263.3K | 75.0K |
| Earning Date | 03-04-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $153,877,000.00 | N/A |
| Revenue This Year | $11.68 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.41 | $1.98 |
| 52 Week High | $4.15 | $20.41 |
| Indicator | BWEN | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 45.14 |
| Support Level | $3.32 | $4.90 |
| Resistance Level | $4.15 | $5.95 |
| Average True Range (ATR) | 0.29 | 0.54 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 56.99 | 32.13 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.